Abstract
CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) expression stimulates the sodium retentive actions of the mineralocorticoid receptor causative of hypertension, probably by means of its ability to substantially increase the level of 6β-hydroxylase activity. Most Black individuals are functional CYP3A5 expressers, and this is a candidate gene for the high incidence of hypertension in Black populations. The study investigates whether CYP3A5 expression results in higher blood pressure in a Ghanaian population. Real-time PCR was used to genotype 898 DNA samples for the CYP3A5*3 and CYP3A5*6 single-nucleotide polymorphisms with technically adequate genotyping for 881 samples. Of these, 803 were genetic CYP3A5 expressers, 44 nonexpressers and 34 uncertain (CYP3A5*3/*6). Although there was a trend in the proportion of hypertensive individuals as CYP3A5 expression decreased, using a two-sided t-test, no statistically significant relationship was established between systolic or diastolic pressure and CYP3A5*3 or CYP3A5*6 genotypes, or their haplotypes (Systolic confidence interval: −8.44 to –7.70, P=0.93, Diastolic confidence interval: −4.89 to 4.85, P=0.99). We conclude, therefore, that there is either no association between CYP3A5 expression and blood pressure or, if there is a relationship, the strength of the association is very small.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gibbs CR, Beevers DG, Lip GY . The management of hypertensive disease in black patients. QJM 1999; 92: 187–192.
Cappuccio FP, Micah FB, Emmett L, Kerry SM, Antwi S, Martin-Peprah R et al. Prevalence, detection, management, and control of hypertension in Ashanti, West Africa. Hypertension 2004; 43: 1017–1022.
Baker EH, Ireson NJ, Carney C, Markandu ND, MacGregor GA . Transepithelial sodium absorption is increased in people of African origin. Hypertension 2001; 38: 76–80.
Lamba JK, Lin YS, Schuetz EG, Thummel KE . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–1294.
Busi F, Cresteil T . CYP3A5 mRNA degradation by nonsense-mediated mRNA decay. Mol Pharmacol 2005; 68: 808–815.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
Coto E, Tavira B, Marín R, Ortega F, López-Larrea C, Ruiz-Ortega M et al. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem Biophys Res Commun 2010; 397: 576–579.
Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A . CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75: 1059–1069.
Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P et al. Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927–F931.
Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297–1300.
Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC et al. Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294–298.
Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF et al. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am J Pharmacogenomics 2005; 5: 191–195.
Zhang L, Miyaki K, Wang W, Muramatsu M . CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens 2010; 24: 345–350.
Ferraresso M, Turolo S, Ghio L, Tirelli AS, Belingheri M, Villa R et al. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors. Clin Exp Hypertens 2011; 33: 359–365.
Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, Navis G . The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 2005; 15: 831–837.
Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE . CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 2005; 15: 737–741.
Cappuccio FP, Kerry SM, Micah FB, Plang-Rhule J, Eastwood J . A community programme to reduce salt intake and blood pressure in Ghana [ISRCT N88789643]. BMC Public Health 2006; 6: 13.
Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP . A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol Cell Physiol 1998; 274: C1245–C1252.
Xi B, Wang C, Liu L, Zeng T, Liang Y, Li J et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res 2011; 34: 1216–1220.
Acknowledgements
The original study was supported by a Wellcome Trust Project grant in 2000 (060415/Z/00/Z).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Fisher, D., Plange-Rhule, J., Moreton, M. et al. CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population. J Hum Hypertens 30, 778–782 (2016). https://doi.org/10.1038/jhh.2016.25
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2016.25
This article is cited by
-
Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Scientific Reports (2021)